This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

IMAAVY™ (nipocalimab-aahu)

Medical Information

IMAAVY - Preparation for Intravenous Infusion Using Diluents Other than Normal Saline in Patients with Generalized Myasthenia Gravis

Last Updated: 05/30/2025

Summary

  • The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
  • IMAAVY must be diluted with 0.9% sodium chloride injection prior to administration.1 
  • Please refer to the Dosage and Administration section of the full Prescribing Information for complete instructions on the preparation and administration of IMAAVY. 

Literature search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) conducted on 16 May 2025 did not identify any relevant citations pertaining to this topic.

References

1 IMAAVY (nipocalimab-aahu) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/IMAAVY-pi.pdf